Detalhe da pesquisa
1.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34252375
2.
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Anticancer Drugs
; 30(4): 394-401, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30875348
3.
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 141-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25519041
4.
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Breast Cancer Res Treat
; 147(1): 61-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25086636
5.
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
Breast
; 72: 103575, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37690320
6.
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
NPJ Breast Cancer
; 8(1): 106, 2022 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117201
7.
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.
Cancers (Basel)
; 14(3)2022 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158789
8.
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Eur J Cancer
; 160: 100-111, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34801353
9.
Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores.
Cancers (Basel)
; 13(4)2021 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33671376
10.
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Eur J Cancer
; 145: 44-52, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423006
11.
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases.
Cancers (Basel)
; 12(10)2020 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998430
12.
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
J Am Heart Assoc
; 9(23): e018143, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33191846
13.
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
JAMA Oncol
; 6(5): 744-748, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32163106
14.
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Eur J Cancer
; 106: 181-192, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30528802
15.
Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study.
J Cancer Res Clin Oncol
; 139(12): 2047-56, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24072232